Quote | Lobe Sciences Ltd (OTCMKTS:LOBEF)
Last: | $0.01675 |
---|---|
Change Percent: | 7.46% |
Open: | $0.0155 |
Close: | $0.01675 |
High: | $0.01675 |
Low: | $0.0155 |
Volume: | 19,348 |
Last Trade Date Time: | 05/08/2024 03:00:00 am |
News | Lobe Sciences Ltd (OTCMKTS:LOBEF)
12-month data confirming that L-130 is the first reported stable oral psilocin First-in-Man clinical data demonstrates the superior PK profile of L-130 2023 sales of $1.1M (CAD) for Altemia ® Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"...
Phase 1 results show significantly increased bioavailability for its stable psilocin compared to psilocybin L-130 Phase 2 Trial Planned for 2024 Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformat...
Message Board Posts | Lobe Sciences Ltd (OTCMKTS:LOBEF)
Subject | By | Source | When |
---|---|---|---|
$LOBEF Lobe Sciences Provides Update For 2023 Milestones https://finance.yahoo. | Mrogers23 | investorshub | 01/18/2023 2:02:50 PM |
$LOBEF $LOBE https://m.facebook.com/story.php?story_fbid=pfbid02C76XCRoPZmEQQaC | StarChild1 | investorshub | 01/17/2023 10:14:05 AM |
LOBEF LOBE SCIENCES LTD. LOBEF (OTCQB) LOBE.CN (CSE) Summary Stock Price: | Mrogers23 | investorshub | 01/16/2023 9:58:46 PM |
I got 8300 shares, hoping for big big | FlipFlopopotamus | investorshub | 08/18/2022 3:33:42 PM |
pennyMoMo: (CSE: $LOBE) (OTCQB: $LOBED)- Lobe Sciences Ltd. Announces Regulatory and Clinical Develo | pennyMoMo | investorshangout | 07/07/2022 5:39:20 PM |
News, Short Squeeze, Breakout and More Instantly...
Lobe Sciences Ltd Company Name:
LOBEF Stock Symbol:
OTCMKTS Market:
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.&nbs...
12-month data confirming that L-130 is the first reported stable oral psilocin First-in-Man clinical data demonstrates the superior PK profile of L-130 2023 sales of $1.1M (CAD) for Altemia ® Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"...
Phase 1 results show significantly increased bioavailability for its stable psilocin compared to psilocybin L-130 Phase 2 Trial Planned for 2024 Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformat...